Clinical Trial Update: A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating ASP7147 in patients with diarrhea-predominant irritable bowel syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome Diarrhea Predominant

Drugs mentioned

• ASP7147 (ASP7147)

Snippet

Sponsor: Seldar Pharma, Inc. | Conditions: Diarrhea Predominant Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED